Correlation of MRI-Derived Apparent Diffusion Coefficients in Newly Diagnosed Gliomas with [¹⁸F]-Fluoro-L-Dopa PET: What Are We Really Measuring with Minimum ADC?

References

1. 1.↵
   1. DeAngelis LM

   . Brain tumors. N Engl J Med 2001;344:114–23

   CrossRefPubMedWeb of Science
2. 2.↵
   1. Johnson PC,
   2. Hunt SJ,
   3. Drayer BP

   . Human cerebral gliomas: correlation of postmortem MR imaging and neuropathologic findings. Radiology 1989;170:211–17

   PubMedWeb of Science
3. 3.↵
   1. Jacobs AH,
   2. Thomas A,
   3. Kracht LW,
   4. et al

   . ¹⁸F-fluorothymidine and ¹¹C-methymethionine as markers of increased transport and proliferation in brain tumors. J Nucl Med 2005;46:1948–58

   Abstract/FREE Full Text
4. 4.↵
   1. Chen W,
   2. Silverman DH,
   3. Delaloye S,
   4. et al

   . ¹⁸F-FDOPA PET imaging of brain tumors: comparison study with ¹⁸F-FDG PET and evaluation of diagnostic accuracy. J Nucl Med 2006;47:904–11

   Abstract/FREE Full Text
5. 5.↵
   1. Ledezma CJ,
   2. Chen W,
   3. Sai V,
   4. et al

   . ¹⁸F-FDOPA PET/MRI fusion in patients with primary/recurrent gliomas: initial experience. Eur J Radiol 2009;71:242–48

   CrossRefPubMed
6. 6.↵
   1. Kim S,
   2. Chung JK,
   3. Im SH,
   4. et al

   . 11C-methionine PET as a prognostic marker in patients with glioma: comparison with 18F-FDG PET. Eur J Nucl Med Mol Imaging 2005;32:52–59

   CrossRefPubMed
7. 7.↵
   1. Cha S

   . Update on brain tumor imaging: from anatomy to physiology. AJNR Am J Neuroradiol 2006;27:475–87

   FREE Full Text
8. 8.↵
   1. Kang Y,
   2. Choi SH,
   3. Kim YJ,
   4. et al

   . Gliomas: histogram analysis of apparent diffusion coefficient maps with standard- or high-b-value diffusion-weighted MR imaging: correlation with tumor grade. Radiology 2011;261:882–90

   CrossRefPubMedWeb of Science
9. 9.↵
   1. Murakami R,
   2. Hiarir T,
   3. Sugahara T,
   4. et al

   . Grading astrocytic tumors by using apparent diffusion coefficient parameters: superiority of a one- versus two-parameter pilot method. Radiology 2009;251:838–45

   CrossRefPubMedWeb of Science
10. 10.↵
    1. Zonari P,
    2. Baraldi P,
    3. Crisi G,
    4. et al

    . Multimodal MRI in the characterization of glial neoplasms: the combined role of single-voxel MR spectroscopy, diffusion imaging and echo-planer perfusion imaging. Neuroradiology 2007;49:795–803

    CrossRefPubMedWeb of Science
11. 11.↵
    1. Catalaa I,
    2. Henry R,
    3. Dillion WP,
    4. et al

    . Perfusion, diffusion and spectroscopy values in newly diagnosed cerebral gliomas. NMR Biomed 2006;19:463–75

    CrossRefPubMedWeb of Science
12. 12.↵
    1. Higano S,
    2. Yun X,
    3. Kumabe T,
    4. et al

    . Malignant astrocytic tumors: clinical importance of apparent diffusion coefficient in prediction of grade and prognosis. Radiology 2006;241:839–46

    CrossRefPubMedWeb of Science
13. 13.↵
    1. Holodny AI,
    2. Makeyev S,
    3. Beattie BJ,
    4. et al

    . Apparent diffusion coefficient of glial neoplasms: correlation with fluorodeoxyglucose-position-emission tomography and gadolinium-enhanced MR imaging. AJNR Am J Neuroradiol 2010;31:1042–48

    Abstract/FREE Full Text
14. 14.↵
    1. Ricci PE,
    2. Karis JP,
    3. Heiserman JE,
    4. et al

    . Differentiating recurrent tumor from radiation necrosis: time for re-evaluation of position emission tomography. AJNR Am J Neuroradiol 1998;19:407–13

    Abstract
15. 15.↵
    1. Becherer A,
    2. Karanikas G,
    3. Szabo M,
    4. et al

    . Brain tumor imaging with PET: a comparison between [18F]fluorodopa and [11C]methionine. Eur J Nucl Med Mol Imaging 2003;30:1561–67

    CrossRefPubMed
16. 16.↵
    1. Schiepers C,
    2. Chen W,
    3. Cloughesy T,
    4. et al

    . 18F-FDOPA kinetics in brain tumors. J Nucl Med 2007;48:1651–61

    Abstract/FREE Full Text
17. 17.↵
    1. Fueger BJ,
    2. Czernin J,
    3. Cloughesy T,
    4. et al

    . Correlation of 6–18F-fluoro-L-dopa PET with proliferation and tumor grade on newly diagnosed and recurrent gliomas. J Nucl Med 2010;51:1532–38

    Abstract/FREE Full Text
18. 18.↵
    1. Namavari M,
    2. Bishop A,
    3. Satyamurthy N,
    4. et al

    . Regioselective radiofluorodestannylation with [18F]F2 and [18F]Ch3COOF: a high yield synthesis of 6-[¹⁸F]fluoro-L-dopa. Int J Rad Appl Instrum A 1992;43:989–96

    CrossRefPubMedWeb of Science
19. 19.↵
    1. Nuyts J,
    2. Michel C,
    3. Dupont P

    . Maximum-likelihood expectation-maximization reconstruction of sinograms with arbitrary noise distribution using NEC-transformations. IEEE Trans Med Imaging 2001;20:365–75

    CrossRefPubMedWeb of Science
20. 20.↵
    1. Kinahan PE,
    2. Townsend DW,
    3. Beyer T,
    4. et al

    . Attenuation correction for a combined 3D PET/CT scanner. Med Phys 1998;25:2046–53

    CrossRefPubMedWeb of Science
21. 21.↵
    1. Rose SE,
    2. Pannek K,
    3. Bell C,
    4. et al

    . Direct evidence of intra- and interhemispheric corticomotor network degeneration in amyotrophic lateral sclerosis: an automated MRI structural connectivity study. Neuroimage 2012;59:2661–69

    CrossRefPubMedWeb of Science
22. 22.↵
    1. Bai Y,
    2. Alexander DC

    . Model-based registration to correct for motion between acquisitions in diffusion MR imaging. In: IEEE International Symposium on Biomedical Imaging: From Nano to Macro, London, UK. 2008;1–4:947–50
23. 23.↵
    1. Rohde GK,
    2. Barnett AS,
    3. Basser PJ,
    4. et al

    . Comprehensive approach for correction of motion and distortion in diffusion-weighted MRI. Magn Reson Med 2004;51:103–14

    CrossRefPubMedWeb of Science
24. 24.↵
    1. Morris D,
    2. Nossin-Manor R,
    3. Taylor MJ,
    4. et al

    . Preterm neonatal diffusion processing using detection and replacement of outliers prior to resampling. Magn Reson Med 2011;66:92–101

    CrossRefPubMed
25. 25.↵
    1. Tournier JD,
    2. Calamante F,
    3. Connelly A

    . Robust determination of the fiber orientation distribution in diffusion MRI: non-negativity constrained super-resolved spherical deconvolution. Neuroimage 2007;35:1459–72

    CrossRefPubMedWeb of Science
26. 26.↵
    1. Ourselin S,
    2. Roche A,
    3. Subsol G,
    4. et al

    . Reconstructing a 3D structure from serial histological sections. Image and Vision Computing 2001;19:25–31

    CrossRef
27. 27.↵
    1. Vees H,
    2. Senthamizhchelvan S,
    3. Miralbell R,
    4. et al

    . Assessment of various strategies for 18F-FET PET-guided delineation of target volumes in high-grade glioma patients. Eur J Nucl Med Mol Imaging 2009;36:182–93

    CrossRefPubMed
28. 28.↵
    1. Hakyemez B,
    2. Erdogan C,
    3. Yildirim N,
    4. et al

    . Glioblastoma multiforme with atypical diffusion-weighted MR findings. Br J Radiol 2005;78:989–92

    Abstract/FREE Full Text
29. 29.↵
    1. Stadnik TW,
    2. Chaskis C,
    3. Mihotte A,
    4. et al

    . Diffusion-weighted MR imaging of intracerebral masses: comparison with conventional MR imaging and histological findings. AJNR Am J Neuroradiol 2001;22:969–76

    Abstract/FREE Full Text
30. 30.↵
    1. Mills SJ,
    2. Soh C,
    3. Rose CJ,
    4. et al

    . Candidate biomarkers of extravascular extracellular space: q direct comparison of apparent diffusion coefficient and dynamic contrast-enhanced MRI imaging—derived measurement of the volume of the extravascular extracellular space in glioblastoma multiforme. AJNR Am J Neuroradiol 2010;31:549–53

    Abstract/FREE Full Text
31. 31.↵
    1. Baehring JM,
    2. Bi WL,
    3. Bannykh S,
    4. et al

    . Diffusion MRI in the early diagnosis of malignant glioma. J Neurooncol 2007;82:221–25

    CrossRefPubMed
32. 32.↵
    1. Lope-Piedrafita S,
    2. Garcia-Martin ML,
    3. Galons JP,
    4. et al

    . Longitudinal diffusion tensor imaging in a rat brain glioma model. NMR Biomed 2008;21:799–808

    CrossRefPubMedWeb of Science
33. 33.↵
    1. Rajendran JG,
    2. Mankoff DA,
    3. O'Sullivan F,
    4. et al

    . Hypoxia and glucose metabolism in malignant tumors: evaluation by [18F]fluoromisonidazole and [18F]fluorodeoxyglucose positron emission tomography imaging. Clin Cancer Res 2004;10:2245–52

    Abstract/FREE Full Text
34. 34.↵
    1. Gupta A,
    2. Young RJ,
    3. Karimi S,
    4. et al

    . Isolated diffusion restriction preceded the development of enhancing tumor in a subset of patients with glioblastoma. AJNR Am J Neuroradiol 2011;32:1301–06

    Abstract/FREE Full Text
35. 35.↵
    1. Ellingson BM,
    2. Cloughesy TF,
    3. Lai A,
    4. et al

    . Graded functional diffusion map-defined characteristics of apparent diffusion coefficients predict overall survival in recurrent glioblastoma treated with bevacizumab. Neuro Oncol 2011;13:1151–61

    Abstract/FREE Full Text
36. 36.↵
    1. Moffat BA,
    2. Chenevert TL,
    3. Lawrence TS,
    4. et al

    . Functional diffusion map: a noninvasive MRI biomarker for early stratification of clinical brain tumor response. Proc Natl Acad Sci U S A 2005;102:5524–29

    Abstract/FREE Full Text
37. 37.↵
    1. DeLano MC,
    2. Cooper TG,
    3. Siebert JE,
    4. et al

    . High-b-value diffusion-weighted MR imaging of adult brain: image contrast and apparent diffusion coefficient map features. AJNR Am J Neuroradiol 2000;21:1830–36

    Abstract/FREE Full Text